Evidence map›Paper›PMID 40181505›Full record

ArticlePhotochemistry and photobiology

Investigation of TNBC metastatic potential following synergistic photodynamic therapy and chemotherapy.

Jeanne Duong, Rachel A McGinn, Nashielli Diaz, Rebecca Crawley, Deepti H Srinivasan, Jasmine Kwan, Marvin Xavierselvan, Madeleine J Oudin, Srivalleesha Mallidi

Abstract read
In one paragraph

Article in Photochemistry and photobiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jeanne DuongDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Rachel A McGinnDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Nashielli DiazDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Rebecca CrawleyDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Deepti H SrinivasanDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Jasmine KwanDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Marvin XavierselvanDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.ORCID 0000-0002-8361-7318
Madeleine J OudinDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Srivalleesha MallidiDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.ORCID 0000-0003-1547-1764

Funding

Investigating mechanisms of chemoresistance in triple-negative breast cancerR01CA255742 · NCI · TUFTS UNIVERSITY MEDFORD · PI Madeleine Julie Oudin · 2022 to 2026
$1.8M
Image-guided oxygen enhanced photodynamic therapy with multi-functional nanodroplets to improve head and neck cancer treatment outcomesR01CA266701 · NCI · TUFTS UNIVERSITY MEDFORD · PI Srivalleesha Mallidi · 2022 to 2026
$1.7M
NCI NIH HHS R01 CA255742NCI NIH HHS R01CA255742NCI NIH HHS R01 CA266701NCI NIH HHS R01CA266701
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer due to a lack of targetable receptors and a high rate of metastasis. The current standard of care for TNBC involves neoadjuvant chemotherapy, such as doxorubicin (DOX), a systemic intervention that affects both cancerous and healthy growing cells throughout the body. In contrast, photodynamic therapy (PDT) offers a minimally invasive alternative, utilizing photosensitizers like benzoporphyrin derivative (BPD) activated by a specific wavelength of light to induce localized cell death. While PDT, both as a standalone treatment and in combination with chemotherapy, has been shown to enhance treatment efficacy in TNBC, its effects on metastatic potential remain poorly understood. To address this knowledge gap, we utilize in vitro assays characterizing cell morphology and invasion as predictors of in vivo metastasis of human TNBC cell lines (BT-20, MDA-MB-231, LM2) following treatments with BPD-PDT alone and in combination with DOX. In this study, we observed that both treatments administered individually demonstrated high sensitivity in BT-20 cells, moderate sensitivity in LM2 cells, and the lowest sensitivity in MDA-MB-231 cells. Comparatively, we found that the combination treatment is most synergistic in LM2 cells and least in BT-20 cells. To assess metastatic potential, we characterized changes in in vitro cell morphology after administering BPD-PDT alone. We discovered that sublethal doses of BPD-PDT alone reduce 3D single-cell and spheroid invasion in LM2 and BT-20 cells, suggesting a decrease in metastatic potential. In contrast, the combination treatment reduced spheroid invasion and led to a more significant increase in pro-apoptotic factors in LM2 and MDA-MB-231 cells compared to BT-20 cells. Overall, our findings highlight the distinct impacts of BPD-PDT alone and the synergistic effects of combination treatment on metastatic potential in TNBC.

Indexed as

DoxorubicinPhotochemotherapyPhotosensitizing AgentsTriple Negative Breast NeoplasmsCell Line, TumorDrug SynergismFemaleHumansNeoplasm MetastasisDoxorubicinPhotosensitizing Agentsbenzoporphyrin derivativeBPD PDTcell invasionchemotherapycombination therapydoxorubicinmetastatic potentialphotodynamic therapyspheroid modelssynergyTNBCtriple‐negative breast cancertumor invasion

Identifiers

PMID40181505
PMCPMC12674661

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.